Neurosense TherapeuticsNRSN
13F holders, Q3 2024 (September 30)7holders
3new positions
3sold out
1famous investor
$1.27avg. 13F price*
At the end of Q3 2024, 7 institutions reported holding Neurosense Therapeutics Ltd. (NRSN) in their 13F filings, unchanged from Q2 2024. 3 opened new positions and 3 sold out. The largest holders were Cantor Fitzgerald, L. P. ($101K), XTX Topco Ltd ($58K) and Meitav Investment House Ltd. ($51K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Neurosense Therapeutics Ltd.
- CUSIP
- M74240108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $160K |
| Exits | 3 | $1.8M |
All 13F filers, Q2 2024 → Q3 2024: 139,743 shares bought and 1,585,554 shares sold, net −1,445,811 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| Cantor Fitzgerald, L. P. | 0.01% | New | 79,492 | $101K |
| XTX Topco Ltd | 0.00% | Add +40.9% | 45,996 | $58K |
| Meitav Investment House Ltd. | 0.00% | No change | 40,000 | $51K |
| Citadel Advisors | 0.00% | New | 34,280 | $44K |
| Commonwealth Equity Services, LLC | 0.00% | New | 12,625 | $16K |
| Geode Capital Management, LLC | 0.00% | No change | 11,963 | $15K |
| Cwm, LLC | 0.00% | No change | 1,000 | $1K |
"% of holder's portfolio" is NRSN's weight in each manager's 13F, not the share of Neurosense Therapeutics Ltd. the manager owns.